Dance Biopharma made a mistake going into the inhalable insulin market. just ask MNKD.
What happened to Matinas Biopharma's game changing catalysts in 2016? It's lipid nanocrystal technology is not unique (Ascendia has a jump start on that). MAT2203 has a fairly tight market, small target population, small profitability (if any). They should have started development with MAT2501 first which has a much larger market and a greater chance of success.
At least going by share performance or product choice neither are stellar.
News 
Market Data 
Discover 
AI
